AB
ABSI.O
—
NASDAQ
Biotechnology
Absi.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,1B USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-4 297,0 %
ROE
-60,8 %
Net margin
-4 113,7 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$7,64
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Absci Corp operates in the biotechnology sector within the Health Care industry, generating minimal revenue of $2.8 million while incurring significant operating losses of $120.3 million.
Business. Absci Corp operates in the biotechnology sector within the Health Care industry, generating minimal revenue of $2.8 million while incurring significant operating losses of $120.3 million.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY9 analysts
8 buy1 hold0 sell
Avg 12m price target8,03
Analyst recommendations
9 analysts · consensus BuyBuy8
Hold1
Sell0
12-month price target
8,03
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
9 analysts · indicative
Ownership→
FMR LLC
largest disclosed fund holder
Profitability→
-60,8 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ABSI.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Absci Corp operates in the biotechnology sector within the Health Care industry, generating minimal revenue of $2.8 million while incurring significant operating losses of $120.3 million.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATED(a) Capital structure and liquidity: Absci Corp maintains a debt-free balance sheet with a debt-to-equity ratio of 0.0. The company holds $20.0 million in cash and equivalents against total liabilities of $26.8 million. With total assets of $216.3 million and total equity of $189.4 million, the firm exhibits a price-to-book ratio of 5.62. Operating cash flow is negative at -$92.9 million, indicating a reliance on equity financing or existing cash reserves to fund operations. Capital expenditure is minimal at $1.1 million.
(b) Profitability and returns: The company is not yet profitable, reporting a net income of -$115.2 million and an operating income of -$120.3 million. Return on equity is -60.8% and return on assets is -53.3%, reflecting the early-stage, R&D-intensive nature of the business. The enterprise value to EBITDA is negative at -8.69, and the EV-to-revenue ratio is extremely high at 373.38, consistent with pre-commercial biotechnology firms.
Key takeaways
- Absci Corp is a pre-profitability biotechnology firm with $2.8 million in revenue and $115.2 million in net losses.
- The company is debt-free with $20.0 million in cash, but operating cash flow is negative at -$92.9 million.
- Valuation multiples are extreme, with an EV-to-revenue of 373.38 and a P/B of 5.62, reflecting high growth expectations.
- Analyst sentiment is positive, with a mean recommendation of 2.00 and a median price target of $9.00.
- Risk assessment flags low liquidity and dilution risks, with no immediate filing-based concerns.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$8,02
Market cap
$1.07B
Enterprise valueⓘ
$1.05B
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
5.6x
P / Tangible bookⓘ
5.6x
Tangible book
$189.4M
Net cashⓘ
$20.0M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
-53.2%
ROEⓘ
-60.8%
Cash conversionⓘ
81.0%
CapEx / revenueⓘ
39.5%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships8 disclosed relationships · 2 types · extracted from filings & disclosures
Partners2
ASTRAZENECA PLCAZN.LPartner95%Source ↗
MERCK & CO., INC.MRK.OPartner95%Source ↗
Subsidiaries6
EX21:1c71c2bda894EX21:1c71c2bda894Subsidiarie97%
EX21:46d9c8e66ef4EX21:46d9c8e66ef4Subsidiarie97%
EX21:5697021bfab6EX21:5697021bfab6Subsidiarie97%
EX21:ba28491394a5EX21:ba28491394a5Subsidiarie97%
EX21:cb4a368fea63EX21:cb4a368fea63Subsidiarie97%
EX21:ffa5a62b0262EX21:ffa5a62b0262Subsidiarie97%
Supply chain
Vendors → ABSI ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,85
Predicted surprise
+0,00
Beat probability
45 %
Analysts
9
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-08-02 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,80 |
| Revenue | —no estimate | —no estimate | 7,1M USD |
| Operating income | —no estimate | —no estimate | -130,0M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution10 analysts
Strong buy2
Buy7
Hold1
Sell0
Strong sell0
12-month price target$13,88 · Median $14,00
Low $10,00High $17,00
Operating income · consensus-130,0M USD
EPS surprise
−5,7 %
reported vs consensus · miss
Revenue surprise
−60,7 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$4,20
Mean$8,03
Median$9,00
High$10,00
Spot$8,02
+0.1 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-4 297,0 %Bottom quartile
Net Margin-4 113,7 %Bottom quartile
ROE-60,8 %Below median
Capex / Rev39,5 %Best in class
D/E0,00Above median
Cash Conv0,81Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 2 614 401 sh1 exercises · 12 grants10 insiders
- Director · Stock Option (right to buy) → Common StockAcquired 39 800 @ $7,34grant · 2026-06-04
- Director · Stock Option (right to buy) → Common StockAcquired 39 800 @ $7,34grant · 2026-06-04
- Director · Stock Option (right to buy) → Common StockAcquired 39 800 @ $7,34grant · 2026-06-04
- Director · Stock Option (right to buy) → Common StockAcquired 39 800 @ $7,34grant · 2026-06-04
- Director · Stock Option (right to buy) → Common StockAcquired 39 800 @ $7,34grant · 2026-06-04
- Director · Stock Option (right to buy) → Common StockAcquired 39 800 @ $7,34grant · 2026-06-04
- Director · Stock Option (right to buy) → Common StockAcquired 22 800 @ $2,80grant · 2026-03-02
- Chief Legal Officer · Stock Option (right to buy) → Common StockAcquired 356 300 @ $2,80grant · 2026-03-02
- CFO / CBO · Stock Option (right to buy) → Common StockAcquired 534 400 @ $2,80grant · 2026-03-02
- Director, Chief Executive Officer · Stock Option (right to buy) → Common StockAcquired 1 603 200 @ $2,80grant · 2026-03-02
- SVP, CAO · Stock Option (right to buy) → Common StockAcquired 195 900 @ $2,80grant · 2026-03-02
- Director, Chief Executive Officer · Stock Option (right to buy) → Common StockDisposed 396 399 @ $1,21exercise · 2026-02-23
- SVP, CAO · Stock Option (right to buy) → Common StockAcquired 59 400 @ $2,94grant · 2026-01-28
Actions
Ask Handelsavisen
— missing data
Data sources
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- ABSCI CORP Market data — financials · 2026-08-02
- reconciler_enqueue (reconciler) on ABSI.O · 2026-08-02
- Absci Corp Market data — analyst estimates · 2026-08-02
- ABSI.O HA canonical relationships · 2026-08-02
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,00 %$68M
- Institutional Investor · as of 2026-03-310,00 %$10M
- Institutional Investor · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$22M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2025-12-310,00 %$28M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-06-300,00 %$16M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net buying5 buys · 2 sellsnet $801K11 insiders · last 365d
- Director · Common StockBought 12 900 @ $11,54$149K · 2026-06-30
- Director, Chief Executive Officer · Common StockOther 59 896 @ $10,07$603K · 2026-06-24
- Director · Common StockOther 10 100 · 2026-06-04
- Director · Common StockOther 10 100 · 2026-06-04
- Director · Common StockOther 10 100 · 2026-06-04
- Director · Common StockOther 10 100 · 2026-06-04
- Director · Common StockOther 10 100 · 2026-06-04
- Director · Common StockOther 10 100 · 2026-06-04
- CFO / CBO · Common StockOther 8 319 @ $6,75$56K · 2026-05-31
- Director · Common StockBought 37 453 @ $5,36$201K · 2026-05-13
- Chief Innovation Officer · Common StockBought 100 000 @ $2,29$229K · 2026-03-12
- SVP, CAO · Common StockOther 5 282 @ $2,80$15K · 2026-03-03
- CFO / CBO · Common StockOther 10 848 @ $2,80$30K · 2026-03-03
- Chief Innovation Officer · Common StockOther 1 257 @ $2,80$4K · 2026-03-03
- Director, Chief Executive Officer · Common StockOther 25 316 @ $2,80$71K · 2026-03-03
- Chief Legal Officer · Common StockOther 9 825 @ $2,80$28K · 2026-03-03
- CFO / CBO · Common StockOther 8 307 @ $2,74$23K · 2026-03-02
- Director · Common StockOther 5 800 · 2026-03-02
- Chief Legal Officer · Common StockOther 90 300 · 2026-03-02
- Director, Chief Executive Officer · Common StockOther 406 200 · 2026-03-02
- SVP, CAO · Common StockOther 49 600 · 2026-03-02
- CFO / CBO · Common StockOther 135 400 · 2026-03-02
- Director · Common StockBought 75 095 @ $2,74$206K · 2026-02-27
- Director, Chief Executive Officer · Common StockOther 396 399 @ $1,21$480K · 2026-02-23
- Director, Chief Executive Officer · Common StockOther 267 008 @ $2,65$708K · 2026-02-23
Short positioning
35.8Mshares short-3.2% vs prior
7.93days to cover
67.9%short of daily vol
376.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ABSI.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data— missing data
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30INSIDERSzela Mary T bought 12.9k sh — Director ~$149k
2026-06-24 00:00 UTCINSIDER13 insider transactions — 2026-06 · net sell $603k 6 derivative
2026-06-24INSIDERMcClain Sean transacted 59.9k sh — Director, Chief Executive Officer ~$603k
2026-06-04INSIDERMCGINNIS KAREN K transacted 10.1k sh — Director
2026-06-04INSIDERPangalos Menelas N transacted 10.1k sh — Director
2026-06-04INSIDERVAN HOUTEN FRANS transacted 10.1k sh — Director
2026-06-04INSIDERRabinovitsj Daniel A transacted 10.1k sh — Director
2026-06-04INSIDERSirosh Joseph transacted 10.1k sh — Director
2026-06-04INSIDERSzela Mary T transacted 10.1k sh — Director
2026-06-04INSIDERVAN HOUTEN FRANS acquired 39.8k sh Stock Option (right to buy) — Director
2026-06-04INSIDERRabinovitsj Daniel A acquired 39.8k sh Stock Option (right to buy) — Director
2026-06-04INSIDERSirosh Joseph acquired 39.8k sh Stock Option (right to buy) — Director
2026-06-04INSIDERMCGINNIS KAREN K acquired 39.8k sh Stock Option (right to buy) — Director
2026-06-04INSIDERSzela Mary T acquired 39.8k sh Stock Option (right to buy) — Director
2026-06-04INSIDERPangalos Menelas N acquired 39.8k sh Stock Option (right to buy) — Director
2026-05-31 00:00 UTCINSIDER2 insider transactions — 2026-05 · net buy $145k
2026-05-31INSIDERJonasson Zachariah transacted 8.3k sh — CFO / CBO ~$56k
2026-05-13INSIDERPangalos Menelas N bought 37.5k sh — Director ~$201k
2026-03-12 00:00 UTCINSIDER17 insider transactions — 2026-03 · $399k gross 5 derivative
2026-03-12INSIDERBusch Andreas bought 100.0k sh — Chief Innovation Officer ~$229k
2026-03-03INSIDERMcClain Sean transacted 25.3k sh — Director, Chief Executive Officer ~$71k
2026-03-03INSIDERBusch Andreas transacted 1.3k sh — Chief Innovation Officer ~$4k
2026-03-03INSIDERJonasson Zachariah transacted 10.8k sh — CFO / CBO ~$30k
2026-03-03INSIDERBedrick Todd transacted 5.3k sh — SVP, CAO ~$15k
2026-03-03INSIDERWalker Shelby J. transacted 9.8k sh — Chief Legal Officer ~$28k
2026-03-02INSIDERPangalos Menelas N transacted 5.8k sh — Director
2026-03-02INSIDERJonasson Zachariah transacted 8.3k sh — CFO / CBO ~$23k
2026-03-02INSIDERBedrick Todd transacted 49.6k sh — SVP, CAO
2026-03-02INSIDERJonasson Zachariah transacted 135.4k sh — CFO / CBO
2026-03-02INSIDERWalker Shelby J. transacted 90.3k sh — Chief Legal Officer
2026-03-02INSIDERMcClain Sean transacted 406.2k sh — Director, Chief Executive Officer
2026-03-02INSIDERMcClain Sean acquired 1.60M sh Stock Option (right to buy) — Director, Chief Executive Officer
Showing the 40 most recent of 58 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage